13 results about "Tumor response" patented technology

The present invention relates to antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and / or expand T effector cell populations or function. For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.

This application relates to the field of tumor treatment technology, specifically to a drug combination and evaluation method for improving the sensitivity of MSS CRC to anti-PD-1 / PD-L1 therapy. The drug combination comprises vancomycin and an immune checkpoint inhibitor. Vancomycin is used to remodel the gut microbiota and reduce L-asparagine levels; the immune checkpoint inhibitor is used to activate CD8. + T-cell anti-tumor response. By combining vancomycin with immune checkpoint inhibitors, the antigen-presenting capacity of dendritic cells is enhanced, thereby increasing the sensitivity of MSS CRC to anti-PD-1 or anti-PD-L1 immunotherapy. This application focuses on the upstream initiation link of gut microbiota-metabolites-dendritic cells-immune activation, relieving the inhibition of dendritic cell antigen presentation by L-asparagine and enhancing CD8+. + T cell activation and tumor immune response enhance the sensitivity of MSS-type colorectal cancer to anti-PD-1 / PD-L1 therapy.

This invention relates to an oral nanomedicine antigen delivery system and its construction method and application, belonging to the field of oral nanomaterials technology; the construction method includes the following steps: (1) preparation of OM nanoparticle suspension; (2) preparation of cationic liposome suspension; (3) preparation of cationic liposome suspension loaded with OM / BF; (4) construction of oral nanomedicine antigen delivery system. This invention breaks through multiple barriers in the gastrointestinal tract, improves drug bioavailability, and achieves precise immune tracking through the OVA tumor antigen model, simulating in vivo anti-tumor CTL response, thereby exerting anti-tumor effects synergistically at the cellular, tissue, and immune levels, effectively solving the problems of poor water solubility and low delivery efficiency of the active ingredient bufotoxin in traditional Chinese medicine. At the same time, through macrophage-mediated immune regulation and precise drug release, it improves targeting and treatment efficiency, opening up a new avenue for tumor immunotherapy with oral nanomedicine.

An adaptive radiotherapy system (100) with biophysical real-time monitoring of the tissue response, wherein the system (100) comprises: a module (1) for real-time biophysical tissue response monitoring, configured to acquire live data on the physiological response and tissue response from a treatment area of ​​a patient during irradiation; a module (2) for localizing patient anatomy and motion detection, configured to detect position changes, organ movements and target shifts in real time; an engine (3) for adaptive treatment planning and dose recalculation, configured to dynamically update a radiotherapy treatment plan based on data received from the module (1) for real-time biophysical monitoring of tissue response and from the module (2) for localizing patient anatomy and motion detection; an engine for predictive modeling of tissue response (4) configured to estimate short-term tissue response, tumor response and normal tissue tolerance using patient data from current and previous sessions; an interface for controlling and modulating the beam (5) which is functionally coupled to a radiation delivery device and configured to modify one or more beam parameters in real time; a safety check and treatment lock control (6) configured to compare current treatment conditions with one or more allowable thresholds and selectively interrupt, stop, or release radiation delivery; and a module (7) for clinical review, data logging and treatment evaluation, configured to store treatment response data, generate session-related adjustment protocols and provide one or more recommendations for subsequent fractions, wherein the system (100) adaptively modifies the radiation output in response to continuously monitored biophysical tissue conditions of the patient.

The application discloses a paclitaxel treatment response prediction method and system for triple-negative breast cancer patients, and the method comprises the following steps: obtaining single-cell transcriptome data, bulk transcriptome data and paclitaxel sensitivity data of triple-negative breast cancer patients before and after treatment and preprocessing; constructing a regression model of immune microenvironment and tumor response, calculating the response score of immune cell subgroups, screening key immune cell subgroups related to paclitaxel treatment response, performing differential expression analysis on the pre-treatment sample, constructing a paclitaxel IC50 prediction model, and dividing the sample into a high-sensitivity group and a low-sensitivity group; constructing a treatment response prediction model and outputting a prediction result. The technical scheme integrates the dynamic changes of the immune microenvironment, the transcriptome characteristics and the drug sensitivity data, realizes accurate prediction of the paclitaxel treatment response of the triple-negative breast cancer patients before treatment, and provides a scientific basis for formulating an individualized treatment plan.

This invention discloses a high-load XOR tumor-targeting therapy nanoplatform based on ROS activity and its applications, belonging to the field of nanobiomaterials. This high-load XOR tumor-targeting therapy nanoplatform, using a zeolite imidazole framework-8 (ZIF-8) as a carrier, contains xanthine oxidoreductase (XOR) with cellular enzymatic activity. It possesses the ability to target tumor cells and induce intracellular reactive oxygen species (ROS), leading to tumor cell death. Induction of intracellular ROS in tumor macrophages (TAMs) also supports the differentiation of macrophages into M1 types. ROS-induced apoptosis in tumor cells produces a series of tumor-associated antigens, which further promotes the infiltration and activation of macrophages in the tumor microenvironment. This, in turn, leads to increased infiltration of CD8+ T cells in the tumor, whose cytokine profile shows cytotoxic effects, indicating successful induction of an adaptive anti-tumor response. This novel nanomaterial offers a promising new strategy for the immunotherapy of gastric diseases.

Provided herein are methods for making a tumor infiltrating lymphocytes (TILs) product enriched with neoantigen-reactive T cells (NARTs), comprising: generating a plurality of TIL populations by fractioning a tumor sample; selecting one or more TIL populations enriched with NARTs by profiling the plurality of TIL populations using multiplex digital PCR (dPCR); and preferentially expanding the NARTs by co-culturing the one or more TIL populations enriched with NARTs with tumor cells from the tumor sample in a first cell culture medium to generate the TIL product enriched with NARTs. Further provided is a method for assessing tumor reactivity of a population of T cells, comprising measurement of the expression level of a panel of target genes of the population of T cells.

This invention relates to the field of biomedical technology, providing a method for preparing a drug-eluting microsphere suspension, the drug-eluting microsphere suspension, and its applications. The method includes: S1. Removing the storage solution from the drug-eluting microspheres to obtain a microsphere precipitate; S2. Adding a chemotherapy drug solution to the microsphere precipitate to load the drug into the microspheres; S3. Mixing physiological saline and a non-ionic contrast agent at a volume ratio of 1.5:1 to prepare a dilution medium; S4. Adding the dilution medium prepared in step S3 to the microspheres after drug loading in step S2, so that the total suspension volume reaches a preset multiple of the microsphere precipitate volume, obtaining a microsphere suspension; S5. Shaking the microsphere suspension obtained in step S4 to mix thoroughly. This invention significantly reduces postoperative chemical stimulation pain by increasing the dilution factor of the drug-eluting microsphere suspension, while unexpectedly improving tumor response, achieving a synergistic effect of pain reduction and efficacy enhancement.

Various embodiments of the invention provide compositions of tumor infiltrating lymphocytes (TILs) enriched in tumor reactive cells, methods for manufacturing TILs enriched in tumor reactive cells and methods and uses of the provided enriched tumor reactive TILs for treating cancer in a human or other subject. Among the provided embodiments of TIL compositions may include those that exhibit substantial tumor reactivity activity, including degranulation and the ability to express one or more of IFN-gamma and TNF-alpha, in response to antigen presenting cells presenting neo antigenic peptides.

The present disclosure relates to fusion proteins comprising a mutant IL-2 polypeptide subunit and one or two antigen binding domains (e.g., VHH antibodies) that specifically bind to an antigen expressed on the surface of immune cells such as tumor reactive T cells expressing CD8 and / or PD1. The fusion can also comprise a half-life extending protein subunit such as an Ig1 Fc region monomer polypeptide. The present disclosure also relates to the use of these fusion proteins as therapeutic agents, for example, in pharmaceutical compositions for treating cancer and autoimmune disorders.

The application discloses a method for improving anti-tumor response by enhancing cellular immune response, comprising administering a nucleic acid molecule encoding an antigen membrane protein to a subject in need, wherein the antigen membrane protein is an antigen membrane protein with a front signal peptide segment removed, and belongs to the technical field of biotechnology; the method disclosed by the application enhances and accelerates the cellular immune response of a receptor, thereby improving the anti-tumor activity, and has the potential for clinical application.

This invention relates to a tumor efficacy evaluation system and the application of single-cell transcriptome sequencing in tumor efficacy evaluation. The tumor efficacy evaluation system includes: a sample acquisition module for acquiring paraffin-embedded samples of lesions at different stages from the same patient being evaluated, the paraffin samples containing tumor tissue; an information acquisition module for acquiring corresponding tumor microenvironment information based on each paraffin sample, the tumor microenvironment information including cell type-related information; and an analysis module for analyzing and comparing the tumor microenvironment information to obtain cellular information for tumor efficacy evaluation. The tumor efficacy evaluation is realistic, accurate, and comprehensive. This invention also discloses the application of single-cell transcriptome sequencing in tumor efficacy evaluation.